Related Experiment Video

Updated: Jul 3, 2026

Manipulation of Epileptiform Electrocorticograms (ECoGs) and Sleep in Rats and Mice by Acupuncture
09:06

Manipulation of Epileptiform Electrocorticograms (ECoGs) and Sleep in Rats and Mice by Acupuncture

Published on: December 22, 2016

Levetiracetam in continuous spike waves during slow-wave sleep syndrome

Shi-Bing Wang1, Wen-Chin Weng, Pi-Chuan Fan

  • 1Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.

Pediatric Neurology
|July 22, 2008
PubMed

Insights

Levetiracetam effectively treats epilepsy with continuous spike waves during slow-wave sleep (CSWS) in children, reducing seizure frequency. However, young children may experience a high relapse rate of CSWS.

Area of Science:

  • Pediatric Neurology
  • Epileptology
  • Clinical Neuroscience

Background:

  • Epilepsy with continuous spike waves during slow-wave sleep (CSWS) is a rare epilepsy syndrome.
  • Understanding the clinical presentation and treatment outcomes is crucial for effective management.

Purpose of the Study:

  • To investigate the clinical characteristics of children diagnosed with CSWS.
  • To evaluate the treatment response and relapse rates associated with levetiracetam in this pediatric population.

Main Methods:

  • Retrospective review of clinical data for six children diagnosed with CSWS.
  • Analysis of neuroimaging findings, seizure frequency, and response to levetiracetam.
  • Monitoring for relapse of electrical status epilepticus during sleep pattern.

Main Results:

  • The most common sign was increased seizure frequency (100%).
  • Levetiracetam showed initial efficacy in five out of six children.
  • A 40% relapse rate was observed in two 5-year-old children within 4-5 months.

Conclusions:

  • Levetiracetam is an effective treatment for CSWS in children.
  • Younger children with CSWS may have a higher risk of relapse, necessitating continued monitoring.

More Related Videos

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement06:58

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
REM Sleep Behavior Disorder01:15

REM Sleep Behavior Disorder

REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...